Sarepta Therapeutics

SRPT Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$23.23

+4.97% today

52W: $10.42 – $64.80

52W Low: $10.42 Position: 23.6% 52W High: $64.80

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

7.64x

Forward Price/Earnings

P/S Ratio

1.11x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.4B

Market Capitalization

Revenue Growth

-32.7%

YoY Revenue Growth

Profit Margin

-32.45%

Net profit margin

ROE

-53.47%

Return on Equity

Beta

0.28

Market sensitivity

Short Interest

25.26%

% of float sold short

Avg. Volume

3,030,490

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Hold

23 analysts

Avg. Price Target

$21.65

-6.79% upside

Target Range

$5.00 – $38.00

About the Company

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 835 Exchange: NMS